Pliant Therapeutics Inc
$ 1.29
0.78%
26 Feb - close price
- Market Cap 78,655,000 USD
- Current Price $ 1.29
- High / Low $ 1.30 / 1.25
- Stock P/E N/A
- Book Value 3.26
- EPS -2.86
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.64 %
- 52 Week High 3.46
- 52 Week Low 1.09
About
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$3.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-07 | 2024-05-06 | 2024-02-27 | 2023-11-09 | 2023-08-09 | 2023-05-09 | 2023-03-09 |
| Reported EPS | -0.43 | -0.71 | -0.92 | -0.82 | -0.95 | -0.92 | -0.78 | -0.69 | -0.7 | -0.7 | -0.67 | -0.72 |
| Estimated EPS | -0.56 | -0.6595 | -0.7469 | -0.9552 | -0.97 | -0.85 | -0.77 | -0.81 | -0.77 | -0.71 | -0.67 | -0.7 |
| Surprise | 0.13 | -0.0505 | -0.1731 | 0.1352 | 0.02 | -0.07 | -0.01 | 0.12 | 0.07 | 0.01 | 0 | -0.02 |
| Surprise Percentage | 23.2143% | -7.6573% | -23.1758% | 14.1541% | 2.0619% | -8.2353% | -1.2987% | 14.8148% | 9.0909% | 1.4085% | 0% | -2.8571% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLRX
2026-02-23 13:43:55
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is scheduled to participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Bernard Coulie, M.D., Ph.D., President and CEO, and Keith Cummings, M.D., CFO, will participate in a fireside chat on February 25, 2026, at 2:40 p.m. ET. A live webcast and replay will be available on the company's investor relations website.
2026-02-23 13:40:00
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Bernard Coulie, M.D., Ph.D., CEO, and Keith Cummings, M.D., CFO, will hold a fireside chat virtually on February 25, 2026, at 2:40 p.m. Eastern Time. A live webcast and replay of the session will be available through the company's investor relations website.
2026-02-23 08:01:00
Pliant Therapeutics, a clinical-stage biotechnology company, announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Bernard Coulie (President and CEO) and Keith Cummings (CFO) will conduct a fireside chat on February 25, 2026, at 2:40 p.m. EST. The company focuses on integrin-based therapeutics, with a lead program for solid tumors and other candidates for fibrosis-related diseases.
2026-02-23 08:00:00
Pliant Therapeutics, Inc. announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, held virtually from February 25-26, 2026. The company's President and CEO, Bernard Coulie, and CFO, Keith Cummings, will lead a fireside chat on February 25, 2026, at 2:40 p.m. Eastern Time. A live webcast and subsequent replay will be available on Pliant's Investor Relations website.
2026-02-23 08:00:00
Pliant Therapeutics, Inc. announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, held virtually from February 25-26, 2026. President and CEO Bernard Coulie, M.D., Ph.D., and CFO Keith Cummings, M.D., will participate in a fireside chat on February 25, 2026, at 2:40 p.m. Eastern Time. A live webcast and archive will be available on the company's investor relations website.
2026-02-23 02:52:02
Pliant Therapeutics (PLRX) is scheduled to release its Q4 2025 earnings before market open on Monday, March 2nd, with analysts expecting a loss of ($0.44) per share. The company's shares opened at $1.24, with a market cap of $76.2 million, and a consensus analyst rating of "Reduce" with an average price target of $3.92. Insider transactions indicate CEO Bernard Coulie sold a portion of his shares, while institutional ownership remains high with several firms increasing their stakes.
